Cana treatment enhanced hippocampal‐dependent learning and memory, markedly reduced AD pathology, and reprogrammed key molecular pathways linked to energy metabolism, neuroinflammation, and insulin signaling. This evidence concerns the gene INS and Alzheimer disease.